

 **NOWDiagnostics®**

Our lab – at the tip of your finger.®

INTRODUCING

ADEXUSDx® COVID-19

Total Antibody Rapid Test

Featuring NEW Touch-to-Test Technology

Sample is applied directly to the tip of the test


The ADEXUSDx® COVID-19 Test is a rapid serology test that detects total antibodies to SARS-CoV-2. It provides in-field lab accurate results within 15 minutes, using as little as a drop of blood.

SIMPLE

- No buffers or external reagents
- No lab equipment
- No in demand ancillary items
- No refrigeration

ACCURATE



- Highly sensitive and specific
- Detects total antibody = all immunoglobins including IgG, IgM and IgA
- Detects past and present COVID-19 infections



Administering Test*

FINGER STICK METHOD

1. Perform finger stick.
2. Touch the drop of blood to the tip of the test.




3. Set timer for 15 minutes and read result.



TRANSFER DEVICE METHOD (Emergency Use Authorized)

1. Apply sample to the test with a transfer device.




2. Set timer for 15 minutes and read result.




INTERPRETATION OF RESULTS


A band of any signal intensity appearing at the Test Line (T) is considered positive for COVID-19.



Positive Result



Negative Result



Invalid Result



Invalid Result

* For complete instructions, refer to the Instructions For Use before administering the test.

Visit C19Development.com for more information.

Description	Quantity	Catalog Number
ADEXUSDx COVID-19 Assay, Box	25	8075-25
ADEXUSDx COVID-19 Assay, Box	50	8075-50
ADEXUSDx COVID-19 Assay, Box	1000	8075-1000
ADEXUSDx COVID-19 Control Set, Box	1	475.002



The ADEXUSDx COVID-19 Test has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. It is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.